---
title: Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use
nct_id: NCT06719180
overall_status: RECRUITING
phase: PHASE4
sponsor: MediSys Health Network
study_type: INTERVENTIONAL
primary_condition: Hysterectomy
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06719180.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06719180"
ct_last_update_post_date: 2025-01-07
last_seen_at: "2026-05-12T06:58:51.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

**Official Title:** A Prospective Randomized Controlled Trial of Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

**NCT ID:** [NCT06719180](https://clinicaltrials.gov/study/NCT06719180)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** MediSys Health Network
- **Conditions:** Hysterectomy, Post Operative Analgesia
- **Start Date:** 2024-12-01
- **Completion Date:** 2025-10-31
- **CT.gov Last Update:** 2025-01-07

## Brief Summary

The purpose of this study is to determine whether an injection of a local anesthetic (Bupivacaine with epinephrine) in the vaginal cuff prior to closure would result in less immediate postoperative pain medication and increase patient comfort/satisfaction.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients 18 years and older requiring total laparoscopic hysterectomy with or without bilateral salpingo-oophorectomy for benign conditions
* Presence of malignancy

Exclusion Criteria:

* Conversion to laparotomy

  * Previous multiple abdominal and/or pelvic surgeries
  * Significant medical comorbidities or cardiac history
  * Poor initial Aldrete score4 (\<10)
  * Significant pre-op pain medication use
  * Contraindication to any medication that would be used in the study (Bupivacaine, epinephrine, tramadol or oxycodone)
```

## Arms

- **Vaginal Cuff Anesthesia** (EXPERIMENTAL)
- **Vaginal Cuff Saline** (PLACEBO_COMPARATOR)

## Interventions

- **Bupivacain** (DRUG) — Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area
- **Saline (NaCl 0,9 %) (placebo)** (OTHER) — A saline placebo

## Primary Outcomes

- **Milligrams of Morphine Equivalent Used** _(time frame: From enrollment to end of treatment at 4 hours.)_

## Secondary Outcomes

- **Counts of Non-Opioid Analgesics Used** _(time frame: From enrollment to end of treatment at 4 hours.)_
- **Patient Change in Pain Score (0-10)** _(time frame: From Baseline to end of treatment at 4 hours)_

## Locations (1)

- Flushing Hospital Medical Center, Flushing, New York, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `locations.flushing hospital medical center|flushing|new york|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06719180.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06719180*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*